劲方医药(2595.HK)孖展超购逾1389倍

格隆汇
Yesterday

生物制药公司劲方医药-B(2595.HK)明日(16日)截飞,截至目前,券商累计为其借出2196.43亿港元孖展,以公开发售集资额1.58亿港元计,相当于超购逾1389倍。劲方医药专注于肿瘤以及自体免疫和炎症性疾病领域的新治疗方案开发,预期周五(19日)挂牌,集资最多15.82亿港元,中信证券为保荐人。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10